BACKGROUND In Switzerland, the heptavalent (PCV7) and 13-valent pneumococcal conjugate vaccine (PCV13) were recommended for all infants aged <2 years in 2007 and 2011, respectively. Due to herd effects, a protective impact on the invasive pneumococcal disease (IPD) rates in adults had been expected. METHODS Within this study, data from the nationwide mandatory surveillance was analyzed for all adult patients ≥16 years with IPD of known serotype/serogroup during 2003-2012. Trend (for IPD cases from 2003 to 2012) and logistic regression analyses (2007-2010) were performed to identify changes in serotype distribution and to identify the association of serotypes with age, clinical manifestations, comorbidities and case fatality, respec...
Background: Immunocompromising conditions and advanced age (>= 65 years) are associated with a high ...
Streptococcus pneumoniae is a major cause of disease, ranging from uncomplicated respiratory infecti...
BACKGROUND:Ontario, Canada introduced a publicly-funded 13-valent pneumococcal conjugate vaccine (PC...
AbstractBackgroundIn Switzerland, the heptavalent (PCV7) and 13-valent pneumococcal conjugate vaccin...
<div><p>This study describes the effects of the introduction of universal infant pneumococcal conjug...
This study describes the effects of the introduction of universal infant pneumococcal conjugate vacc...
Pneumococcal conjugate vaccines (PCVs) have lowered the incidence of invasive pneumococcal disease (...
Streptococcus pneumoniae serotypes differ in clinical manifestations among adults. Indirect effects ...
Since 2010 the 13-valent pneumococcal conjugate vaccine (PCV13) replaced the 7-valent vaccine (PCV7)...
Abstract Background The pneumococcal conjugate vaccine PCV7 was introduced in Southwest Sweden in th...
The aim of the study was to compare the distribution of the vaccine-serotypes covered by pneumococca...
Pneumococcal conjugate vaccines (PCVs) have lowered the incidence of invasive pneumococcal disease (...
Background. The 13-valent pneumococcal conjugate vaccine (PCV13) has recently been approved for use ...
Serotypes/genotypes causing invasive pneumococcal disease (IPD) in adults are determined by vaccinat...
International audienceBackground: The long-term benefits of pneumococcal conjugate vaccines (PCVs) r...
Background: Immunocompromising conditions and advanced age (>= 65 years) are associated with a high ...
Streptococcus pneumoniae is a major cause of disease, ranging from uncomplicated respiratory infecti...
BACKGROUND:Ontario, Canada introduced a publicly-funded 13-valent pneumococcal conjugate vaccine (PC...
AbstractBackgroundIn Switzerland, the heptavalent (PCV7) and 13-valent pneumococcal conjugate vaccin...
<div><p>This study describes the effects of the introduction of universal infant pneumococcal conjug...
This study describes the effects of the introduction of universal infant pneumococcal conjugate vacc...
Pneumococcal conjugate vaccines (PCVs) have lowered the incidence of invasive pneumococcal disease (...
Streptococcus pneumoniae serotypes differ in clinical manifestations among adults. Indirect effects ...
Since 2010 the 13-valent pneumococcal conjugate vaccine (PCV13) replaced the 7-valent vaccine (PCV7)...
Abstract Background The pneumococcal conjugate vaccine PCV7 was introduced in Southwest Sweden in th...
The aim of the study was to compare the distribution of the vaccine-serotypes covered by pneumococca...
Pneumococcal conjugate vaccines (PCVs) have lowered the incidence of invasive pneumococcal disease (...
Background. The 13-valent pneumococcal conjugate vaccine (PCV13) has recently been approved for use ...
Serotypes/genotypes causing invasive pneumococcal disease (IPD) in adults are determined by vaccinat...
International audienceBackground: The long-term benefits of pneumococcal conjugate vaccines (PCVs) r...
Background: Immunocompromising conditions and advanced age (>= 65 years) are associated with a high ...
Streptococcus pneumoniae is a major cause of disease, ranging from uncomplicated respiratory infecti...
BACKGROUND:Ontario, Canada introduced a publicly-funded 13-valent pneumococcal conjugate vaccine (PC...